Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.
Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.
Ligand has multiple technologies and unpartnered programs available for out-licensing.
Sep 25, 2017 • 9:00 AM EDT
Ligand to Host Analyst Day on November 14th in New York City
Sep 5, 2017 • 8:00 AM EDT
Ligand Announces Top-Line Results from Phase 2 Study of LGD-6972 in Patients with Type 2 Diabetes
Sep 1, 2017 • 9:00 AM EDT
Ligand to Participate in Two Upcoming Investor Conferences
Sep 11, 2017 • 1:45pm EDT
Lotte New York Palace Hotel, New York, NY
See all events
Sep 6, 2017
Aug 7, 2017 • 4:30pm EDT
Nov 14, 2017 • 4:00pm - 5:30pm EDT
New York, NY
Exelixis announces Daiichi's Phase 3 esaxerenone study met primary objective; Japanese filing expected in Q1'18 https://t.co/ETbxbIITk5
Melinta Therapeutics publication highlights Baxdela activity against fluoroquinolone-non-susceptible MRSA pathogens https://t.co/IeNo3kukJh
OmniAb partner HanAll signs agreement with Harbour BioMed to develop novel biologic therapies in greater China https://t.co/7dFG2fgtEZ